The drug should be discontinued if patients develop ALT of ≥5x ULN or ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR (international normalized ratio). This evidence concerns the gene GPT and inflammation.